

Prior Authorization DRUG Guidelines

ANTAGON® (Ganirelix)

Effective Date: 7/28/05

Date Developed: 7/8/05 by C. Wilhelmy MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

(Archived 1/22/19)

Antagon competitively blocks pituitary gonadotropin-releasing (GRH) hormone receptors. This suppresses gonadotropin secretion and luteinizing hormone secretion preventing ovulation until the follicles are of adequate size.

Pre-Authorization Criteria: infertility: used in combination with FSH and hCG to inhibit premature LH surges and thus promote ovarian hyperstimulation (which increases the chance of viable ovum release)

Note: VCHCP requires that Antagon be prescribed by a fertility specialist.

Dosing: 250 mcg subQ per day (after initiating follicle-stimulating hormone on day 2 or 3 of cycle; continued daily until the day of chorionic gonadotropin administration.)

Note: once instructed, patient may self-administer at the same time daily

How Supplied: pre-filled 0.5 mL syringe containing 250 mg ganrilex

Precautions: not to be prescribed if the patient is pregnant; watch for hypersensitivity reactions

Drug Interactions: none documented

REFERENCES

Oberýé, J; Mannaerts, B; Huisman, J; Timmer, C (February 2000). "Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran) administration by Medi-Jector compared to conventional needle injections." *Human reproduction (Oxford, England)* **15** (2): 245–9.

Borm, G., Mannaerts, B., European Orgalutran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. *Hum Reprod.* 2000;15:1490–1498.

European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH agonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. *Hum Reprod.* 2001;16:644–651.

Shapiro, D. Real-life clinical applications of GnRH antagonists: individualization of fertility treatment(American Society for Reproductive Medicine (ASRM) Symposium. October 16, 2002, Seattle, Washington) . *Fertil Steril.* 2003;80:S1–S34.

Copperman, A. Antagonists in poor-responder patients(American Society for Reproductive Medicine (ASRM) Symposium. October 16, 2002, Seattle, Washington) . *Fertil Steril.* 2003;80:S16–S24.

Revision History:

Date Revised: 10/04/11 by A. Reeves, MD

Date Reviewed/No Updates: 4/2/12; 1/16/13 by A. Reeves, MD

Date Approved by P&T Committee: 7/28/05; 10/25/11; 4/24/12; 1/29/13

Date Reviewed/No Updates: 1/28/14 by C. Sanders MD

Date Approved by P&T Committee: 1/28/14

Date Reviewed/Updated: 7/23/15 by C. Sanders MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 01.24.17 by C. Sanders MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check MCG